LEADER
Dr Christina SIMOGLOU KARALI
christinasikar@uoa.gr
Co-LEADERS
Dr Michail SPANOUDAKIS
michail.spanoudakis@nhs.net
Dr Antonio PIERINI
antonio.pierini@unipg.it
How can I participate?
Read the Action Description MoU
Inform the Main Proposer/Chair of your interest (e.papadaki@uoc.gr)
Apply to join your Working Groups of interest
Please note, Management Committee nominations are carried out through the COST National Coordinators
DRUG-INDUCED NEUTROPENIAS BY NOVEL THERAPIES
To date, the understanding of the molecular underpinnings of drug-induced myelosuppression is largely based on the histological analysis of BM trephines and less frequently on a concrete study of the myeloid cell differentiation. This WG aims to overcome the current limitations imposed by the elusive understanding of the molecular signatures of the distinct myeloid progenitor cell populations to establish advanced protocols for the accurate modelling of the clinically observed drug-induced myelosuppression ex vivo. This WG will also contribute to the rationale design of bioinformatics analyses to utilize large scale datasets available for further integrative analyses, but also harmonize the design of upcoming studies using agents devoid of deleterious myelosuppressive phenotypes.
Detailed staging of neutrophil populations and their precursors using multi-omic datasets using transcriptional and epigenetic signatures and GWAS.
Evaluation of the best practices leading to protocol harmonization and eventually fostering the feasibility of integrative analyses. The introduction of more complex systems facilitating the interrogation of the impact of the BM niche and the cross-talk with other crucial immune populations will be attempted.
Evaluation of currently available bioinformatics pipelines and the development of tailored analytical workflows that would focus (a) on addressing the impact of distinct agents on myeloid cell fate commitment through the interaction with specific transcriptional factor/binding partners and (b) on the in-silico prediction of novel pathogenic interactions.
This resource will be designed based on the recommendations from consortium partners to serve as a fully interactive, easily accessible tool facilitating the exploration of complex datasets and supporting novel target discovery.
Milestones:
M4.1. WG Meetings (1st quarter of each year) which will be based on the progress made in WG-4 followed by the respective reports (months 12, 24, 36, 48).
M4.2. Calls for STSMs (2nd and 4th quarter of each year) for training of YRIs on the technologies developed by WG-4 followed by the relative technical and scientific reports (months 12, 24, 36, 48).
M4.3 First release of online reference database (month 30) and follow-up upgrades on a semi-annual basis thereafter (months 36,42,48).
